Over the decades, advances in diagnosis, imaging, interventions, surgery, transplantation, and anticancer therapy have improved survival for patients with hepatocellular carcinoma. However, the overall long-term prognosis for hepatocellular carcinoma patients remains poor. Therefore, there is an urgent need to understand the biology of carcinogenesis, progression, metastasis, recurrence, and resistance to cancer therapies in order to develop new preventive/therapeutic approaches for hepatocellular carcinoma. Recently, in addition to curative treatments such as transplantation, resection, and ablation, tyrosine kinase inhibitors, PD-1 inhibitors, and their combinations have improved progression-free survival and overall survival in patients with unresectable advanced hepatocellular carcinoma. The period has been extended. In addition, antifibrotic, antiviral, and anti-inflammatory agents have been shown to reduce the risk of fibrosis progression and, accordingly, the risk of developing hepatocellular carcinoma.
• Trans-arterial chemoembolization.
• Prognostic Markers.
• Drug Therapy Targeting.
• Clinical trials in Hepatocellular Carcinoma.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
